Literature DB >> 9292532

Seroreactivity to an envelope protein of human T-cell leukemia/lymphoma virus in patients with CD3- (natural killer) lymphoproliferative disease of granular lymphocytes.

T P Loughran1, K G Hadlock, Q Yang, R Perzova, R Zambello, G Semenzato, S K Foung, B J Poiesz.   

Abstract

Natural killer (NK) cells are CD3- large granular lymphocytes (LGL) responsible for immunity against viral infections. A chronic lymphoproliferative disorder of NK cells has been described in which the expanded NK cells display a restricted phenotype and cytotoxic activity. These data raise the hypothesis that proliferating LGL in these patients result from discrete expansions of NK cells responding to an unknown, perhaps viral, antigen. Recently, it was found that mice transgenic for the tax gene of human T-cell leukemia/lymphoma virus (HTLV) develop NK leukemia. Therefore, we studied 15 patients with chronic NK lymphoproliferative disorder for evidence of HTLV infection. Sera were tested using an HTLV-I/II-enzyme linked immunosorbent assay and a modified Western blot assay containing recombinant env proteins. None of the sera met conventional criteria for HTLV seroreactivity. However, sera from 11 patients (73%) reacted with the recombinant HTLV env protein p21E. The anti-p21E reactivity of these sera was then mapped employing the recombinant proteins GD21 and BA21. No reactivity to the immunodominant HTLV epitope GD21 was observed, suggesting that prototypical HTLV infection is unlikely in these patients. This was confirmed by finding no evidence for HTLV nucleic acids by PCR analyses employing primers specific for conserved regions in the env, pol, and pX genes. In contrast, 10 of the 15 sera reacted with the epitope BA21, documenting for the first time an association between a unique seroreactivity and disease. The high incidence of BA21 seroreactivity in these patients suggests that exposure to a protein containing homology to BA21 may be important in the pathogenesis of this lymphoproliferative disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9292532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

2.  Conformation-specific antibodies targeting the trimer-of-hairpins motif of the human T-cell leukemia virus type 1 transmembrane glycoprotein recognize the viral envelope but fail to neutralize viral entry.

Authors:  Antonis Mirsaliotis; Kulpash Nurkiyanova; Daniel Lamb; Jenny M Woof; David W Brighty
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

3.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

4.  Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway.

Authors:  Jun Yang; Xin Liu; Susan B Nyland; Ranran Zhang; Lindsay K Ryland; Kathleen Broeg; Kendall Thomas Baab; Nancy Ruth Jarbadan; Rosalyn Irby; Thomas P Loughran
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

5.  Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+dim chronic natural killer cell large granular lymphocytosis.

Authors:  Margarida Lima; Julia Almeida; Andrés García Montero; Maria dos Anjos Teixeira; Maria Luís Queirós; Ana Helena Santos; Ana Balanzategui; Alexandra Estevinho; Maria del Cármen Algueró; Paloma Barcena; Sónia Fonseca; Maria Luís Amorim; José Manuel Cabeda; Luciana Pinho; Marcos Gonzalez; Jesus San Miguel; Benvindo Justiça; Alberto Orfão
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

6.  Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells.

Authors:  Cristina Gattazzo; Antonella Teramo; Francesca Passeri; Elena De March; Samuela Carraro; Valentina Trimarco; Federica Frezzato; Tamara Berno; Gregorio Barilà; Veronica Martini; Francesco Piazza; Livio Trentin; Monica Facco; Gianpietro Semenzato; Renato Zambello
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

Review 7.  HTLV-1/-2 and HIV-1 co-infections: retroviral interference on host immune status.

Authors:  Elisabetta Pilotti; Maria V Bianchi; Andrea De Maria; Federica Bozzano; Maria G Romanelli; Umberto Bertazzoni; Claudio Casoli
Journal:  Front Microbiol       Date:  2013-12-23       Impact factor: 5.640

Review 8.  Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?

Authors:  Renato Zambello; Antonella Teramo; Gregorio Barilà; Cristina Gattazzo; Gianpietro Semenzato
Journal:  Front Immunol       Date:  2014-02-26       Impact factor: 7.561

9.  B lineage-specific regulation of V(D)J recombinase activity is established in common lymphoid progenitors.

Authors:  Lisa Borghesi; Lih-Yun Hsu; Juli P Miller; Michael Anderson; Leonard Herzenberg; Leonore Herzenberg; Mark S Schlissel; David Allman; Rachel M Gerstein
Journal:  J Exp Med       Date:  2004-02-09       Impact factor: 14.307

10.  Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?

Authors:  Renato Zambello; Antonella Teramo; Cristina Gattazzo; Gianpietro Semenzato
Journal:  Transl Med UniSa       Date:  2014-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.